Literature DB >> 29429013

Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.

Tomi F Akinyemiju1,2,3, Gurudatta Naik4,5, Kemi Ogunsina4, Daniel T Dibaba6, Neomi Vin-Raviv7,8.   

Abstract

BACKGROUND: This study examines whether racial disparities in hospitalization outcomes persist between African-American and White women with ovarian cancer after matching on demographic, presentation, and treatment factors.
METHODS: Using data from the Nationwide Inpatient Sample database, 5,164 African-American ovarian cancer patients were sequentially matched with White patients on demographic (e.g., age, income), presentation (e.g., stage, comorbidities), and treatment (e.g., surgery, radiation) factors. Racial differences in-hospital length of stay, post-operative complications, and in-hospital mortality were evaluated using conditional logistic regression models.
RESULTS: White ovarian cancer patients had relatively higher odds of post-operative complications when matched on demographics (OR 1.35, 95% CI 1.05, 1.74), and presentation (OR 1.28, 95% CI 1.00, 1.65) but not when additionally matched on treatment (OR 1.03, 95% CI 0.78, 1.35). African-American patients had longer in-hospital length of stay (6.96 ± 7.21 days) compared with White patients when matched on demographics (6.37 ± 7.07 days), presentation (6.48 ± 7.16 days), and treatment (6.53 ± 7.59 days). Compared with African-American patients, White patients experienced lower odds of in-hospital mortality when matched on demographics (OR 0.78, 95% CI 0.66, 0.92), but this disparity was no longer significant when additionally matched on presentation (OR 0.88, 95% CI 0.75, 1.04) and treatment (OR 0.95, 95% CI 0.81, 1.12).
CONCLUSION: Racial disparities in ovarian cancer hospitalization outcomes persisted after adjusting for demographic and presentation factors; however these differences were eliminated after additionally accounting for treatment factors. More studies are needed to determine the factors driving racial differences in ovarian cancer treatment in otherwise similar patient populations.

Entities:  

Keywords:  Disparity; Hospitalization; Matching; Mortality; Outcomes; Ovarian cancer

Mesh:

Year:  2018        PMID: 29429013      PMCID: PMC6080617          DOI: 10.1007/s10552-018-1010-7

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  42 in total

1.  Insurance Status and Racial Disparities in Cancer-Specific Mortality in the United States: A Population-Based Analysis.

Authors:  Hubert Y Pan; Gary V Walker; Stephen R Grant; Pamela K Allen; Jing Jiang; B Ashleigh Guadagnolo; Benjamin D Smith; Matthew Koshy; Chad G Rusthoven; Usama Mahmood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-02-09       Impact factor: 4.254

2.  Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.

Authors:  Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver
Journal:  Obstet Gynecol       Date:  2015-04       Impact factor: 7.661

3.  Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database.

Authors:  S A Fedewa; C Lerro; D Chase; E M Ward
Journal:  Gynecol Oncol       Date:  2011-04-03       Impact factor: 5.482

4.  The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women.

Authors:  G Parham; J L Phillips; M L Hicks; N Andrews; W B Jones; H M Shingleton; H R Menck
Journal:  Cancer       Date:  1997-08-15       Impact factor: 6.860

5.  Ovarian cancer outcomes: Predictors of early death.

Authors:  Renata R Urban; Hao He; Raphael Alfonso; Melissa M Hardesty; Heidi J Gray; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2015-12-29       Impact factor: 5.482

6.  Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group.

Authors:  E M John; A S Whittemore; R Harris; J Itnyre
Journal:  J Natl Cancer Inst       Date:  1993-01-20       Impact factor: 13.506

7.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Racial disparities in blacks with gynecologic cancers.

Authors:  John Farley; John I Risinger; G Scott Rose; G Larry Maxwell
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

9.  Predictors of comprehensive surgical treatment in patients with ovarian cancer.

Authors:  Barbara A Goff; Barbara J Matthews; Eric H Larson; C Holly A Andrilla; Michelle Wynn; Denise M Lishner; Laura-Mae Baldwin
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

10.  Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.

Authors:  Caitlin C Murphy; Linda C Harlan; Joan L Warren; Ann M Geiger
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 50.717

View more
  2 in total

1.  Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer.

Authors:  David Banham; David Roder; Dorothy Keefe; Gelareh Farshid; Marion Eckert; Natasha Howard; Karla Canuto; Alex Brown
Journal:  BMC Health Serv Res       Date:  2019-06-14       Impact factor: 2.655

2.  Cancer treatment and the risk of cancer death among Aboriginal and non-Aboriginal South Australians: analysis of a matched cohort study.

Authors:  David Banham; David Roder; Marion Eckert; Natasha J Howard; Karla Canuto; Alex Brown
Journal:  BMC Health Serv Res       Date:  2019-10-29       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.